Takeda to buy Swiss drugmaker Nycomed for $13.6 billion

Reuters

TOKYO (Reuters) - Takeda Pharmaceutical Co <4502.T>, Japan's largest drugmaker, said on Thursday it would buy privately held Swiss rival Nycomed for 9.6 billion euros ($13.6 billion) as it seeks to expand in Europe and emerging markets.

The purchase would also offer Takeda access to lung-disease drug Daxas, just approved in the United States, and a portfolio of over-the-counter consumer products.

Continue Reading Below

Nycomed is majority owned by four private equity firms, led by Nordic Capital with 41 percent. Credit Suisse's DLJ Merchant Banking has 25.6 percent, Coller International Partners 9.7 percent and Avista 8.9 percent.

($1 = 0.707 Euros)

(Reporting by James Topham; Editing by Edwina Gibbs)